Crystal structure of diroximel fumarate, C11H13NO6
Powder DiffractionAbstractThe crystal structure of diroximel fumarate has been solved and refined using synchrotron X-ray powder diffraction data, and optimized using density functional theory techniques. Diroximel fumarate crystallizes in space group P-1 (#2) with a = 6.12496(15), b = 8.16516(18), c = 12.7375(6) Å, α = 85.8174(21), β = 81.1434(12), γ = 71.1303(3)°, V =
James A. Kaduk +2 more
openaire +1 more source
Cognitive impairment and its impact on employment : A qualitative interview-based study involving healthcare professionals and people living with multiple sclerosis [PDF]
Background: Cognitive impairment can considerably impact the work life of people who have multiple sclerosis (MS). Cognitive symptoms are associated with an increased likelihood of unemployment, changes in employment and decreased working hours.
Alexandri, Nektaria +4 more
core +1 more source
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. [PDF]
BACKGROUND Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biological agents.
Baldin, Elisa +10 more
core +2 more sources
Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews. [PDF]
Adv Ther, 2022 Gudesblatt M +7 more
europepmc +1 more source
Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance [PDF]
The Association of British Neurologists last published guidelines on disease-modifying treatment (DMT) in multiple sclerosis (MS) in 2015. Since then, additional DMTs have been licensed and approved for prescribing within the National Health Service for ...
Arun, Tarunya +13 more
core
Montelukast as a Repurposable Additive Drug for Standard-Efficacy Multiple Sclerosis Treatment: Emulating Clinical Trials With Retrospective Administrative Health Claims Data [PDF]
BACKGROUND: Effective and safe treatment options for multiple sclerosis (MS) are still needed. Montelukast, a leukotriene receptor antagonist (LTRA) currently indicated for asthma or allergic rhinitis, may provide an additional therapeutic approach ...
Freeman, Leorah +3 more
core +1 more source
Diroximel Fumarate-Loaded Solid Lipid Nanoparticles (DRF-SLNs) as Potential Carriers for the Treatment of Multiple Sclerosis: Preformulation Study. [PDF]
Int J Mol SciSantonocito D +7 more
europepmc +1 more source
Self-assessment of people with relapsing-remitting and progressive multiple sclerosis towards burden of disease, progression, and treatment utilization: results of a large-scale cross-sectional online survey (MS Perspectives) [PDF]
, 2022 Bayas, Antonios, Christ, M., Schuh, K.
core +1 more source
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study. [PDF]
Adv TherBowen JD +7 more
europepmc +1 more source